SOMERSET, N.J, March 12, 2018 --
MTBC (Nasdaq: MTBC) (Nasdaq: MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced that its Board of Directors has declared monthly cash dividends for its 11% Series A Cumulative Redeemable Perpetual Preferred Stock (“Series A Preferred Stock”) for March, April and May 2018. This represents 30 consecutive months of dividends declared since the Series A Preferred Stock was initially sold in November 2015.
Holders of shares of the Series A Preferred Stock are entitled to receive cumulative cash dividends at the rate of 11% per annum of the $25.00 per share liquidation preference (equivalent to $2.75 per annum per share). Dividends on the Series A Preferred Stock are payable monthly on the 15th day of each month; provided that if any dividend payment date is not a business day, then the dividend may be paid on the next succeeding business day. Dividends are payable to holders of record on the applicable record date, which shall be the last day of the calendar month, whether or not a business day.
MTBC’s Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol “MTBCP.”
The following table shows the monthly dividends and associated record and payment dates:
| March 2018 | April 2018 | May 2018 | |
| Dividend per share | $0.22917 | $0.22917 | $0.22917 |
| Ex-dividend date | March 29, 2018 | April 27, 2018 | May 30, 2018 |
| Record date | March 31, 2018 | April 30, 2018 | May 31, 2018 |
| Payment date | April 16, 2018 | May 15, 2018 | June 15, 2018 |
About MTBC
Medical Transcription Billing, Corp. is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers throughout the United States. Our integrated Software-as-a-Service (or SaaS) platform helps our customers increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. MTBC's common stock trades on the NASDAQ Capital Market under the ticker symbol “MTBC,” and its Series A Preferred Stock trades on the NASDAQ Capital Market under the ticker symbol “MTBCP."
For additional information, please visit our website at www.MTBC.com.
Follow MTBC on TWITTER, LINKEDIN and FACEBOOK.
SOURCE MTBC
Disclaimer
This press release is for information purposes only, and does not constitute an offer to sell or solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Company Contact: Bill Korn Chief Financial Officer Medical Transcription Billing, Corp. [email protected] (732) 873-5133


Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Washington Post Publisher Will Lewis Steps Down After Layoffs
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Instagram Outage Disrupts Thousands of U.S. Users
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



